Science Corp. Secures $230M Funding for Rapid Development of Revolutionary Brain Implant Technology

Revolutionizing the Medical World: Science Corp.’s Breakthrough in Brain-Computer Interface Technology

While the majority of the venture capital industry has been fixated on AI investments, Max Hodak, the co-founder and former president of Neuralink, has been quietly working on a groundbreaking startup. Science Corporation, under Hodak’s leadership, is poised to become the first brain-computer interface company to bring a product to market.

This innovative approach has not gone unnoticed. Science Corp. recently announced a significant milestone, securing $230 million in a Series C funding round. With a post-money valuation of $1.5 billion, the company is attracting attention from investors and industry experts alike.

One of Science Corp.’s key developments is PRIMA, a tiny chip designed to restore functional vision in individuals with advanced macular degeneration. By implanting the chip in the eye and pairing it with camera-equipped glasses, the technology has shown promising results in clinical trials.

Although Science Corp. acquired PRIMA’s assets from Pixium Vision and refined the technology, the company’s own trials have yielded impressive outcomes. In studies involving 47 patients in Europe and the U.S., 80% experienced significant improvements in visual acuity, enabling them to read letters, numbers, and words.

According to Max Hodak, the restoration of fluent reading ability in blind patients is a groundbreaking achievement never before seen in medical science. The success of Science Corp.’s device has even garnered recognition from Time magazine, further solidifying the company’s position as a leader in the field.

While the timeline for PRIMA’s availability to patients remains uncertain, Science Corp. is actively pursuing regulatory approvals. The company has submitted a CE mark application to the European Union and anticipates approval by mid-2026, paving the way for a European launch.

Germany is likely to be the initial market for Science Corp.’s revolutionary technology, thanks to the country’s streamlined processes for introducing new medical innovations. In the U.S., ongoing discussions with the FDA are progressing towards potential regulatory approval.

Expanding beyond macular degeneration, Science Corp. is broadening its trial program to include Stargardt disease and retinitis pigmentosa, two common causes of vision loss in young adults. This strategic move aims to address a wider range of retinal conditions and provide innovative solutions for patients.

The latest funding round, totaling $230 million, will fuel the commercialization of PRIMA and support Science Corp.’s diverse research initiatives. In addition to the brain-computer interface technology, the company is exploring a biohybrid neural interface program that involves growing engineered neurons on a specialized device placed on the brain’s surface.

Introducing a new venture called Vessel, Science Corp. is venturing into organ preservation technology. By developing miniaturized perfusion solutions, the company aims to revolutionize organ transportation, allowing organs to be transported via commercial flights or maintained by patients at home.

Notable investors in Science Corp.’s Series C round include Lightspeed Venture Partners, Khosla Ventures, Y Combinator, Quiet Capital, and IQT. With a total funding of $490 million and a workforce of 150 employees, the company is well-positioned to drive innovation and shape the future of medical technology.

Update: The initial valuation of the company has been corrected to reflect the post-money valuation, not pre-money valuation.